Načítá se...
CBX Chromodomain Inhibition Enhances Chemotherapy Response in Glioblastoma Multiforme
Glioblastoma multiforme (GBM) lacks effective therapeutic options leaving patients with a survival time of approximately one year. Recently, the alteration of chromatin modulators has been implicated in the pathogenesis and chemoresistance of numerous cancers; in particular, the Polycomb Group Prote...
Uloženo v:
| Vydáno v: | Yale J Biol Med |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
YJBM
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5168823/ https://ncbi.nlm.nih.gov/pubmed/28018136 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|